Clinical trials: Grass Allergy
Grass Pollen Allergy
GRASS (Grass MATA MPL Real-world Assessment Study)
Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.
- Trial name
- GRASS (NCT07412990)
- Testing
- Grassmuno®
- Where
- Germany
- Volunteers
- 1,000 people
- Sponsor
- Allergy Therapeutics
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Grass Pollen Allergy
Phase II Study of Grass Pollen Allergy Vaccine BM32
The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study…
- Trial name
- NCT01538979
- Testing
- BM32
- Where
- 11 sites in Austria, Belgium and 4 more
- Volunteers
- 181 people
- Sponsor
- Biomay AG
Grass Allergy, Rhinoconjunctivitis
Grass Observational Study
Grass pollen allergens are universally recognised as a major cause of allergic diseases in humans, including asthma, allergic rhinitis, conjunctivitis and dermatitis.
- Trial name
- NCT02075138
- Where
- 7 sites in United States, Argentina and 1 more
- Volunteers
- 109 people
- Sponsor
- Circassia Limited
Rhinoconjunctivitis, Grass Allergy
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT02292875
- Where
- 2 sites in Canada
- Volunteers
- 84 people
- Sponsor
- Circassia Limited
Grass Pollen Allergy
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
The trial is performed to assess efficacy and safety of the Grass Pollen Allergoid in Allergic Rhinoconjunctivitis
- Trial name
- NCT00263601
- Testing
- Allergovit 6-grasses
- Where
- Germany
- Volunteers
- 154 people
- Sponsor
- Allergopharma GmbH & Co. KG
Grass Pollen Allergy, Hay Fever
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT01308021
- Testing
- gpASIT+TM
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 202 people
- Sponsor
- BioTech Tools S.A.
Grass Pollen Allergy
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
The trial is performed to asses efficacy and safety of a sublingual extract of a six grass pollen mixture
- Trial name
- NCT00264459
- Testing
- Grass pollen formulation, Comparator
- Where
- Germany
- Volunteers
- 160 people
- Sponsor
- Allergopharma GmbH & Co. KG
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Follow on Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01923779
- Volunteers
- 163 people
- Sponsor
- Circassia Limited
Grass Allergy, Rhinoconjunctivitis
ToleroMune Grass Exposure Unit Study
Grass pollen allergens are recognised as a major cause of allergic diseases in humans and animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen allergens and between 50-90% of hayfever or seasonal…
- Trial name
- NCT01385800
- Testing
- ToleroMune Grass
- Where
- Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Grass Pollen Allergy
Safety and Dose Finding Trial of BM32 in Subjects Suffering From Grass Pollen Allergy
The study will evaluate the dose response of immunotherapy against grass pollen allergy using the recombinant grass pollen vaccine BM32.
- Trial name
- NCT01445002
- Testing
- BM32
- Where
- Austria
- Volunteers
- 79 people
- Sponsor
- Biomay AG
Allergic Rhinitis, Grass Allergy
Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis
Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases. GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken…
- Trial name
- GT-17 (NCT01728285)
- Testing
- Electronic compliance device (Memozax®)
- Where
- Italy
- Volunteers
- 261 people
- Sponsor
- ALK-Abelló A/S
Allergy to Grass Pollen
Biological Standardization of Lolium Perenne Allergen Extract
The objective of this study is to determine the biologic activity of a Lolium perenne allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01394289
- Testing
- Lolium allergen extract
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy to Grass Pollen
Biological Standardization of Poa Pratensis Allergen Extract
The objective of this study is to determine the biologic activity of a Poa pratensis allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01430117
- Testing
- Four different concentrations of Poa pratensis allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy to Grass Pollen (Dactylis Glomerata)
Biological Standardization of Dactylis Glomerata Allergen Extract
The objective of this study is to determine the biologic activity of a Dactylis glomerata allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01407835
- Testing
- Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy to Grass Pollen (Secale Cereale)
Biological Standardization of Secale Cereale Allergen Extract
The objective of this study is to determine the biologic activity of a Secale cereale allergen extract in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
- Trial name
- NCT01408238
- Testing
- Four different concentrations of Secale cereale allergen extract, positive control and negative control
- Where
- 2 sites in Spain
- Volunteers
- 35 people
- Sponsor
- Laboratorios Leti, S.L.
Grass Pollen Allergy
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis
- Trial name
- NCT00773240
- Testing
- Grazax
- Where
- Denmark
- Volunteers
- 276 people
- Sponsor
- ALK-Abelló A/S